Recursion Pharmaceuticals ($NASDAQ:RXRX) Inc recently received an impressive rating of 50 from InvestorsObserver, placing it amongst the highest in the Healthcare Sector. This high rating makes it a potentially good stock to invest in for those looking to diversify their portfolios. RECURSION PHARMACEUTICALS is a biopharmaceutical company on a mission to discover and develop treatments for diseases using artificial intelligence. The company taps into massive amounts of data from electronic healthcare records and combines that with advances in biology and computer science to discover novel treatments. They are driven by the potential to help millions of patients suffering from diseases with unmet needs.
RECURSION PHARMACEUTICALS believes that through the use of automation, they can reduce the expense and time associated with discovering treatments, making medical breakthroughs faster and more cost-effective. With its innovative approach to developing treatments and its potential to help millions of people, RECURSION PHARMACEUTICALS is sure to be an excellent addition to any investor’s portfolio.
This was in response to the stock’s opening at $10.7 and closing at $11.6, which was an increase of 4.7% from the previous closing price of $11.0. InvestorsObserver’s rating was an indication that Recursion Pharmaceuticals Inc has the potential for future growth in the healthcare sector. It is clear that investors are optimistic about the prospects of this company, which could result in further gains in the stock price. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Recursion Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Recursion Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Recursion Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Recursion Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale’s Star Chart analysis of RECURSION PHARMACEUTICALS reveals strong asset and growth capabilities, and a weak dividend and profitability profile. Specifically, RECURSION PHARMACEUTICALS has an intermediate health score of 6 out of 10, indicating that it is likely to sustain future operations in times of crisis. Based on this assessment, we classify RECURSION PHARMACEUTICALS as a “cheetah” type company – one that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors looking for companies with high growth prospects but a lower level of stability may find RECURSION PHARMACEUTICALS an attractive option. More…
Risk Rating Analysis
Star Chart Analysis
The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.
EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.
Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.
Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.
Recursion Pharmaceuticals Inc is a good buy in the healthcare sector, according to InvestorsObserver’s 50 rating. The stock price has recently experienced an upward trend, indicating a positive outlook from investors. Analyzing the company’s financials reveals a strong balance sheet with a growing revenue stream. The company also has a strong management team and an innovative product pipeline.